Navigation Links
Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture
Date:7/22/2014

(WASHINGTON, July 22, 2014) The American Society of Hematology (ASH) will honor Tomas Ganz, MD, PhD, of the University of California Los Angeles with the 2014 E. Donnall Thomas Lecture for his groundbreaking research in iron homeostasis, including the discovery of the iron-regulatory hormone hepcidin and investigation of its roles in iron metabolism. This award, named after the Nobel Prize Laureate and past Society president E. Donnall Thomas, MD, recognizes pioneering research achievements in hematology that have represented a paradigm shift or significant discovery in the field.

Dr. Ganz will present his lecture, "Iron, Erythropoiesis, and Host Defense: A Mnage Trois," at 9:00 a.m. on Monday, December 8, at the 56th ASH Annual Meeting and Exposition in San Francisco. His lecture will explore the advances in understanding of homeostatic iron regulation and the iron-regulatory responses to the challenges of acute hemorrhage and acute infection. During his lecture, Dr. Ganz will discuss iron deficiency anemia and anemia of inflammation and will expand upon how their frequency may reflect an evolutionary compromise to provide sufficient iron for essential processes while avoiding the tendency of iron to promote microbial infections and cause tissue injury. He will further elucidate insights into several components of iron regulation and response and discuss how the hormone hepcidin is regulated by erythroferrone, interleukin-6, and, to a lesser extent, other cytokines in response to blood loss and infection. Dr. Ganz's lecture will also touch upon how, as understanding of systemic iron homeostasis and its disorders increases, biological targets for diagnostic and therapeutic applications will be identified.

Dr. Ganz has been the leading scientist in the effort to uncover the molecular basis of iron homeostasis and its disorders. He played a pivotal role in the discovery of hepcidin and continues to lead the way in the ongoing exploration of
'/>"/>

Contact: Amanda Szabo
aszabo@hematology.org
202-552-4914
American Society of Hematology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors
2. Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture
3. ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement
4. The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice
5. St. Jude Childrens Research Hospital names James R. Downing, M.D., CEO
6. Barry A. Siegel, M.D., receives 2014 Benedict Cassen Prize for Research in Nuclear Medicine
7. Mathuram Santosham, M.D., receives 2014 Albert B. Sabin Gold Medal Award
8. Molly Carnes, M.D., receives inaugural Linda Joy Pollin Heart Health Leadership Award
9. Francis S. Collins, M.D., Ph.D., to speak at AMP 2014 Annual Meeting
10. BIDMCs Martin Pollak, M.D., elected to National Academy of Sciences
11. Boston Medical Center cardiologist Gary Balady, M.D., receives AHAs Paul Dudley White Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 Cloud ... Live Streaming (HLS) & UStream API’S to serve m3u8 ... wonderful feature for broadcasting live video events with hundreds ... apps. , The App Builder is known for making ... android, iOS, BlackBerry and Windows 8 and already over ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new ... with a bad heart condition. , Clients who have ... insurance if they compare quotes. Most agencies will insure ... on the actual and past medical condition. , ... heart attacks in the past, his or her chances ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) tracer is effective ... still alive, according to a case study conducted at ... at Molecular Neuroimaging (MNI) LLC in New Haven, and ... . , Specifically, the study results suggest that an ... to latch onto a protein called tau that accumulates ...
(Date:9/16/2014)... predict a man,s risk of getting prostate cancer after ... analysis of the cancer,s genetic biomarkers, reported in ... and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished Professor ... large consortia of research hubs around the world, said ... in 80,000 men. , "It,s the largest analysis of ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 An experimental ... concussion-related brain disease while a person is still alive, ... School of Medicine at Mount Sinai, and at Molecular ... 16 in the journal Translational Psychiatry. , Specifically, the ... [18 F]-T807, which is designed to latch onto a ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... province said the SARS virus could be stopped and could ... health department, said the average daily new cases had dropped ... He gave this assurance as he was treating three foreigners, ... were infected.// ,He said the number of cases of ...
... 2003 Annual Meeting of the American Association for Cancer Research, ... means of cancer prognosis than measuring body mass index and ... the measures for detecting breast cancer are perfect, says lead ... ,But, he says that levels of leptin which signals ...
... St Mary's Hospital, Manchester, UK, has shown that family history of ... breast cancer. A survey of a group of 99 women under ... third of them had a strong history of either breast or ... cancer, 44 per cent were found to carry// mutations in the ...
... Kansas have now studied a new electrical device,that ... victims of Parkinson's disease.,This new treatment involves implanting ... of life for Parkinson's patients. This,electrical device helps ... the,signals that otherwise cause disabling tremor. The researchers ...
... long time now a lot of health experts that to ... has been advised we should,drink at least eight 8-ounce glasses ... Researchers from Center for Human Nutrition at the,University of Nebraska ... keep ourselves hydrated.// A group of 27 male volunteers were ...
... the A & A Pain Institute in St Louis, Missouri(A ... of pain), have,found that an anticonvulsant drug levetiracetam brings dramatic ... seven patients between 39 and 67 who had,severe nerve pain ... on,the nerve, analgesic drugs were not effective in relieving the ...
Cached Medicine News:
(Date:9/16/2014)... BETHESDA, Md. , Sept. 16, 2014 ... a biotechnology company developing DCVax® personalized immune therapies for ... the first product to receive formal designation as a ... to Medicines Scheme" (EAMS) launched in the UK in ... a 2-step process for early access approval under the ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
Medicine Products: